Jennifer Ann Johnson, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penicillin G Benzathine | 1 | 2018 | 24 | 0.660 |
Why?
|
| AIDS Vaccines | 5 | 2018 | 938 | 0.610 |
Why?
|
| Syphilis | 1 | 2018 | 227 | 0.540 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2014 | 43 | 0.490 |
Why?
|
| Endocarditis, Bacterial | 2 | 2020 | 455 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 7 | 2020 | 7179 | 0.430 |
Why?
|
| Nasal Cavity | 1 | 2014 | 313 | 0.430 |
Why?
|
| Encephalitis, Viral | 1 | 2012 | 55 | 0.420 |
Why?
|
| HIV-2 | 1 | 2012 | 167 | 0.400 |
Why?
|
| Endocarditis | 4 | 2020 | 350 | 0.400 |
Why?
|
| Actinomycetales | 1 | 2011 | 31 | 0.390 |
Why?
|
| Actinomycetales Infections | 1 | 2011 | 30 | 0.390 |
Why?
|
| Carrier State | 1 | 2014 | 518 | 0.380 |
Why?
|
| Pleurisy | 1 | 2011 | 53 | 0.380 |
Why?
|
| Drug Carriers | 3 | 2018 | 693 | 0.380 |
Why?
|
| Rheumatic Heart Disease | 1 | 2012 | 177 | 0.380 |
Why?
|
| Bacteremia | 3 | 2020 | 962 | 0.360 |
Why?
|
| HIV Infections | 9 | 2018 | 16718 | 0.330 |
Why?
|
| Foot Diseases | 1 | 2010 | 143 | 0.330 |
Why?
|
| Propionates | 1 | 2009 | 169 | 0.320 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 687 | 0.310 |
Why?
|
| Adenoviruses, Human | 3 | 2014 | 257 | 0.310 |
Why?
|
| Anti-HIV Agents | 3 | 2013 | 4256 | 0.300 |
Why?
|
| Acidosis | 1 | 2009 | 272 | 0.290 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 638 | 0.290 |
Why?
|
| Genetic Vectors | 3 | 2018 | 3420 | 0.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 1873 | 0.270 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2020 | 525 | 0.260 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 6172 | 0.250 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 1715 | 0.250 |
Why?
|
| Thromboembolism | 1 | 2010 | 985 | 0.230 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2021 | 3533 | 0.220 |
Why?
|
| Sternotomy | 1 | 2021 | 121 | 0.190 |
Why?
|
| Bone Diseases, Infectious | 1 | 2020 | 18 | 0.190 |
Why?
|
| HIV-1 | 6 | 2018 | 6938 | 0.180 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2021 | 150 | 0.180 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 1623 | 0.160 |
Why?
|
| Doxycycline | 1 | 2018 | 326 | 0.140 |
Why?
|
| Treatment Refusal | 1 | 2020 | 421 | 0.140 |
Why?
|
| Fatal Outcome | 3 | 2010 | 1849 | 0.140 |
Why?
|
| Contact Tracing | 1 | 2018 | 273 | 0.140 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 404 | 0.130 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 4586 | 0.130 |
Why?
|
| Buprenorphine | 2 | 2020 | 640 | 0.130 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 2065 | 0.130 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 1400 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 6352 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 2 | 2010 | 5257 | 0.130 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 4252 | 0.130 |
Why?
|
| Hospitals, Urban | 2 | 2014 | 499 | 0.120 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2014 | 45 | 0.120 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 370 | 0.120 |
Why?
|
| Canarypox virus | 1 | 2013 | 10 | 0.120 |
Why?
|
| Orthopoxvirus | 1 | 2013 | 11 | 0.120 |
Why?
|
| Neck | 1 | 2018 | 696 | 0.120 |
Why?
|
| Viridans Streptococci | 1 | 2012 | 15 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2021 | 1540 | 0.100 |
Why?
|
| Toes | 2 | 2010 | 207 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.100 |
Why?
|
| Minnesota | 1 | 2012 | 344 | 0.100 |
Why?
|
| Gene Products, env | 1 | 2012 | 263 | 0.100 |
Why?
|
| Brain Abscess | 1 | 2012 | 118 | 0.100 |
Why?
|
| Immunity, Mucosal | 1 | 2014 | 490 | 0.100 |
Why?
|
| Brain | 4 | 2012 | 26413 | 0.100 |
Why?
|
| Capsid Proteins | 1 | 2014 | 479 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2012 | 955 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 12961 | 0.090 |
Why?
|
| Ritonavir | 1 | 2012 | 322 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 258 | 0.090 |
Why?
|
| DNA, Ribosomal | 1 | 2011 | 290 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2708 | 0.090 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 341 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 353 | 0.080 |
Why?
|
| Adenoviridae | 1 | 2013 | 1099 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2020 | 2684 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2012 | 2559 | 0.080 |
Why?
|
| Methicillin Resistance | 2 | 2006 | 198 | 0.080 |
Why?
|
| Viral Load | 3 | 2012 | 3300 | 0.080 |
Why?
|
| Infarction | 1 | 2010 | 246 | 0.080 |
Why?
|
| Blood | 1 | 2011 | 598 | 0.080 |
Why?
|
| Staphylococcus aureus | 2 | 2006 | 1451 | 0.080 |
Why?
|
| Vaccines, Synthetic | 3 | 2018 | 634 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2012 | 825 | 0.080 |
Why?
|
| Fontan Procedure | 1 | 2014 | 779 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 1372 | 0.080 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 638 | 0.080 |
Why?
|
| Humans | 26 | 2021 | 744220 | 0.080 |
Why?
|
| Oxacillin | 1 | 2006 | 42 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2020 | 3313 | 0.070 |
Why?
|
| Adenine | 1 | 2012 | 936 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2012 | 1962 | 0.070 |
Why?
|
| Thrombosis | 1 | 2020 | 2968 | 0.070 |
Why?
|
| Fingers | 1 | 2010 | 514 | 0.070 |
Why?
|
| Medical Records | 1 | 2012 | 1413 | 0.070 |
Why?
|
| Male | 16 | 2020 | 350027 | 0.070 |
Why?
|
| Embolism | 1 | 2009 | 409 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2009 | 545 | 0.070 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 1467 | 0.070 |
Why?
|
| Microscopy | 1 | 2011 | 903 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4929 | 0.060 |
Why?
|
| Middle Aged | 12 | 2020 | 213367 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2010 | 1284 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 1265 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2012 | 2902 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 20123 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2010 | 1132 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2020 | 77426 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2014 | 2062 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 464 | 0.050 |
Why?
|
| HIV Antibodies | 3 | 2014 | 1322 | 0.050 |
Why?
|
| Vision Disorders | 1 | 2010 | 1059 | 0.050 |
Why?
|
| Adult | 10 | 2020 | 214035 | 0.050 |
Why?
|
| Placebos | 2 | 2018 | 1677 | 0.050 |
Why?
|
| Bone Wires | 1 | 2021 | 122 | 0.050 |
Why?
|
| Treatment Outcome | 6 | 2021 | 63119 | 0.050 |
Why?
|
| Gene Expression | 1 | 2014 | 7799 | 0.050 |
Why?
|
| Ischemia | 1 | 2010 | 1914 | 0.050 |
Why?
|
| Sternum | 1 | 2021 | 177 | 0.050 |
Why?
|
| Echocardiography | 1 | 2012 | 5103 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4803 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14726 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 35423 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15070 | 0.040 |
Why?
|
| Bone Plates | 1 | 2021 | 468 | 0.040 |
Why?
|
| Female | 11 | 2020 | 380197 | 0.040 |
Why?
|
| Weight Loss | 1 | 2010 | 2622 | 0.040 |
Why?
|
| Vaccines, Subunit | 1 | 2018 | 168 | 0.040 |
Why?
|
| Pulmonary Circulation | 1 | 2020 | 739 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 18116 | 0.040 |
Why?
|
| Naltrexone | 1 | 2020 | 307 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 7908 | 0.040 |
Why?
|
| Catheters | 1 | 2020 | 425 | 0.040 |
Why?
|
| Young Adult | 5 | 2018 | 56436 | 0.040 |
Why?
|
| Methadone | 1 | 2020 | 306 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2018 | 12035 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 3871 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2014 | 40559 | 0.040 |
Why?
|
| Injections | 1 | 2020 | 840 | 0.040 |
Why?
|
| Heart Failure | 1 | 2020 | 10905 | 0.040 |
Why?
|
| Vaccinia virus | 1 | 2018 | 349 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2014 | 1836 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 562 | 0.030 |
Why?
|
| Child | 3 | 2014 | 77679 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15538 | 0.030 |
Why?
|
| Liver | 1 | 2010 | 7472 | 0.030 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 3674 | 0.030 |
Why?
|
| Infant | 2 | 2014 | 35129 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2014 | 130 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2018 | 598 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2014 | 40992 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2014 | 548 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2021 | 1640 | 0.030 |
Why?
|
| Risk Factors | 3 | 2021 | 72280 | 0.030 |
Why?
|
| Propionibacterium acnes | 1 | 2012 | 66 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 1607 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2012 | 25618 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 1912 | 0.030 |
Why?
|
| Adolescent | 4 | 2014 | 85759 | 0.030 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5076 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 231 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 126 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 53280 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 347 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8628 | 0.020 |
Why?
|
| Cryoglobulinemia | 1 | 2009 | 87 | 0.020 |
Why?
|
| Hemianopsia | 1 | 2009 | 122 | 0.020 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2009 | 173 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2009 | 339 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2020 | 9849 | 0.020 |
Why?
|
| Hospitalization | 1 | 2006 | 10262 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2020 | 3114 | 0.020 |
Why?
|
| Colon | 1 | 2014 | 1772 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 1584 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2006 | 277 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 1734 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 1978 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 163253 | 0.010 |
Why?
|
| Haplotypes | 1 | 2010 | 2781 | 0.010 |
Why?
|
| Shock | 1 | 2006 | 318 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 3036 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 643 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2010 | 4012 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 13990 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 6485 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 4385 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2006 | 1179 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 168788 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2010 | 5458 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 12781 | 0.010 |
Why?
|
| Cytokines | 1 | 2014 | 7326 | 0.010 |
Why?
|
| Alleles | 1 | 2010 | 6938 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 2958 | 0.010 |
Why?
|
| Cross Infection | 1 | 2006 | 1416 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 4477 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2009 | 6442 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 13409 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13280 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12244 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2006 | 5316 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12264 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15525 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 18367 | 0.010 |
Why?
|
| Incidence | 1 | 2006 | 20945 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 40063 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 57768 | 0.000 |
Why?
|